ArticleAmerican journal of obstetrics and gynecology2017
Maternal buprenorphine treatment and fetal neurobehavioral development.
Article in American journal of obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Systematic Review: Polysubstance Prevalence Estimates Reported during Pregnancy, US, 2009-2020.Maternal and child health journal · 2023Pooled it
- Effects of an attachment-based intervention on autonomic regulation among opioid-exposed infants.Developmental psychobiology · 2022Trial
- A Scoping Review of Non-Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research.Clinical and translational science · 2026Article
- Animal Models of Prenatal Opioid Exposure: Insights into Impaired Neurodevelopment.Advances in experimental medicine and biology · 2026Review
- Gestational Opioid Exposure: From Morphine to MOUD - How Opioids Impact Offspring Development and Maternal Care.Current topics in behavioral neurosciences · 2025Review
- The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment.Neuropharmacology · 2024Article
- Effects of prenatal opioid exposure on infant sympathetic and parasympathetic nervous system activity.Psychophysiology · 2024Article
- Article
- Opioid, methamphetamine, and polysubstance use: perinatal outcomes for the mother and infant.Frontiers in pediatrics · 2023Review
- Article
- Maternal Serotonin Reuptake Inhibitor Antidepressants Have Acute Effects on Fetal Heart Rate Variability in Late Gestation.Frontiers in psychiatry · 2021Article
- Salivary cortisol levels as a biomarker for severity of withdrawal in opioid-exposed newborns.Pediatric research · 2020Observational
- Prenatal opioid exposure: The next neonatal neuroinflammatory disease.Brain, behavior, and immunity · 2020Article
- Research and policy priorities for addressing prenatal exposure to opioids in Alaska.International journal of circumpolar health · 2019Article
- Prenatal Opioid Exposure: Neurodevelopmental Consequences and Future Research Priorities.Pediatrics · 2019Review
- Early life stress and environmental influences on the neurodevelopment of children with prenatal opioid exposure.Neurobiology of stress · 2018Review
- Fetal assessment in buprenorphine-maintained women using fetal magnetoencephalography: a pilot study.Addiction (Abingdon, England) · 2018Article
- Substance use in pregnancy: The medical challenge.Obstetric medicine · 2018Review
- Maternal buprenorphine treatment and infant outcome.Drug and alcohol dependence · 2017Article
- Gestational buprenorphine-naloxone exposure and fetal neurobehavior.Neurotoxicology and teratologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGestational opioid use/misuse is escalating in the United States; however, little is understood about the fetal effects of medications used to treat maternal opioid use disorders.
objectiveThe purpose of this study was to determine the effect of maternal buprenorphine administration on longitudinal fetal neurobehavioral development. STUDY
designForty-nine buprenorphine-maintained women who attended a substance use disorder treatment facility with generally uncomplicated pregnancies underwent fetal monitoring for 60 minutes at times of trough and peak maternal buprenorphine levels. Data were collected at 24, 28, 32, and 36 weeks gestation. Fetal neurobehavioral indicators (ie, heart rate, motor activity, and their integration [fetal movement-fetal heart rate coupling]) were collected via an actocardiograph, digitized and quantified. Longitudinal data analysis relied on hierarchic linear modeling.
resultsFetal heart rate, heart rate variability, and heart rate accelerations were significantly reduced at peak vs trough maternal buprenorphine levels. Effects were significant either by or after 28 weeks gestation and tended to intensify with advancing gestation. Fetal motor activity and fetal movement-fetal heart rate coupling were depressed from peak to trough at 36 weeks gestation. Polysubstance exposure did not significantly affect fetal neurobehavioral parameters, with the exception that fetuses of heavier smokers moved significantly less than those of lighter smokers at 36 weeks gestation. By the end of gestation, higher maternal buprenorphine dose was related to depression of baseline fetal cardiac measures at trough.
conclusionMaternal buprenorphine administration has acute suppressive effects on fetal heart rate and movement, and the magnitude of these effects increases as gestation progresses. Higher dose (≥13 mg) appears to exert greater depressive effects on measures of fetal heart rate and variability. These findings should be balanced against comparisons to gestational methadone effects, relatively good outcomes of buprenorphine-exposed infants, and recognition of the benefits of medication-assisted treatment for pregnant women with opioid use disorders in optimizing pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.